$5.37 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter

Equities research analysts expect that Gilead Sciences, Inc. (NASDAQ:GILD) will report sales of $5.37 billion for the current quarter, Zacks reports. Seven analysts have provided estimates for Gilead Sciences’ earnings, with estimates ranging from $5.05 billion to $5.64 billion. Gilead Sciences reported sales of $6.51 billion in the same quarter last year, which indicates a negative year over year growth rate of 17.5%. The business is expected to announce its next earnings results on Tuesday, May 1st.

On average, analysts expect that Gilead Sciences will report full year sales of $5.37 billion for the current year, with estimates ranging from $20.31 billion to $21.63 billion. For the next financial year, analysts forecast that the firm will report sales of $20.95 billion per share, with estimates ranging from $19.04 billion to $22.18 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.70 earnings per share.

Several research firms have recently issued reports on GILD. Vetr downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price target for the company. in a research note on Monday, January 29th. Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price target for the company from $88.80 to $76.00 in a research note on Tuesday, January 30th. Morgan Stanley dropped their price target on shares of Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. Bank of America raised their price target on shares of Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a research note on Wednesday, February 7th. Finally, BMO Capital Markets raised their price target on shares of Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research note on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and an average target price of $87.04.

Gilead Sciences (GILD) opened at $80.94 on Wednesday. The stock has a market cap of $105,415.91, a price-to-earnings ratio of 23.26, a PEG ratio of -1.85 and a beta of 1.22. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 2.82%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the sale, the insider now directly owns 3,070,099 shares in the company, valued at $230,196,023.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the sale, the chairman now owns 3,046,766 shares of the company’s stock, valued at $254,587,766.96. The disclosure for this sale can be found here. Insiders sold 418,333 shares of company stock valued at $32,742,108 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC grew its holdings in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after buying an additional 258,005 shares during the last quarter. Macquarie Group Ltd. grew its holdings in shares of Gilead Sciences by 26.6% during the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after buying an additional 100,741 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after buying an additional 116,780 shares during the last quarter. Finally, Toronto Dominion Bank grew its holdings in shares of Gilead Sciences by 19.0% during the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after buying an additional 75,364 shares during the last quarter. Hedge funds and other institutional investors own 75.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “$5.37 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://stocknewstimes.com/2018/02/21/5-37-billion-in-sales-expected-for-gilead-sciences-inc-gild-this-quarter.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply